Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy

作者：Zhu, Guizhi; Lynn, Geoffrey M.; Jacobson, Orit; Chen, Kai; Liu, Yi; Zhang, Huimin; Ma, Ying; Zhang, Fuwu; Tian, Rui; Ni, Qianqian; Cheng, Siyuan; Wang, Zhantong; Lu, Nan; Yung, Bryant C.; Wang, Zhe; Lang, Lixin; Fu, Xiao; Jin, Albert; Weiss, Ido D.; Vishwasrao, Harshad; Niu, Gang; Shroff, Hari; Klinman, Dennis M.; Seder, Robert A.; Chen, Xiaoyuan^*

来源：Nature Communications, 2017, 8(1): 1954.

DOI：10.1038/s41467-017-02191-y

• SERUM-ALBUMIN
• CHECKPOINT BLOCKADE
• IMMUNE-RESPONSES
• SWISS-PDBVIEWER
• LYMPH-NODE
• T-CELLS
• TUMOR
• BINDING
• DELIVERY
• VACCINES

Subunit vaccines have been investigated in over 1000 clinical trials of cancer immunotherapy, but have shown limited efficacy. Nanovaccines may improve efficacy but have rarely been clinically translated. By conjugating molecular vaccines with Evans blue (EB) into albuminbinding vaccines (AlbiVax), here we develop clinically promising albumin/AlbiVax nanocomplexes that self-assemble in vivo from AlbiVax and endogenous albumin for efficient vaccine delivery and potent cancer immunotherapy. PET pharmacoimaging, super-resolution microscopies, and flow cytometry reveal almost 100-fold more efficient co-delivery of CpG and antigens (Ags) to lymph nodes (LNs) by albumin/AlbiVax than benchmark incomplete Freund's adjuvant (IFA). Albumin/AlbiVax elicits similar to 10 times more frequent peripheral antigenspecific CD8(+) cytotoxic T lymphocytes with immune memory than IFA-emulsifying vaccines. Albumin/AlbiVax specifically inhibits progression of established primary or metastatic EG7. OVA, B16F10, and MC38 tumors; combination with anti-PD-1 and/or Abraxane further potentiates immunotherapy and eradicates most MC38 tumors. Albumin/AlbiVax nanocomplexes are thus a robust platform for combination cancer immunotherapy.

• 出版日期2017-12-5
• 单位厦门大学; 中国药科大学